Impact and utility of follicular lymphoma GELF criteria in routine care: an Australasian Lymphoma Alliance study

Allison Barraclough; Shivam Agrawal; Dipti Talaulikar; Geoffrey Chong; Edward Yoo; Chan Y. Cheah; Nunzio Franco; Bianca Nguyen; Howard Mutsando; Fatima Tahir; Judith Trotman; Jing Huang; Colm Keane; Mitchel Lincoln; Tara Cochrane; Anna M. Johnston; Michael Dickinson; Stephen Opat; Zoe K. McQuilten; Erica M. Wood; Gayathri St George; Eliza A. Hawkes

doi:10.3324/haematol.2023.284538

Impact and utility of follicular lymphoma GELF criteria in routine care: an Australasian Lymphoma Alliance study

Allison Barraclough, Shivam Agrawal, Dipti Talaulikar, Geoffrey Chong, Edward Yoo, Chan Y. Cheah, Nunzio Franco, Bianca Nguyen, Howard Mutsando, Fatima Tahir, Judith Trotman, Jing Huang, Colm Keane, Mitchel Lincoln, Tara Cochrane, Anna M. Johnston, Michael Dickinson, Stephen Opat, Zoe K. McQuilten, Erica M. WoodGayathri St George, Eliza A. Hawkes

School of Medicine and Psychology

Research output: Contribution to journal › Article › peer-review

5 Citations (Scopus)

Abstract

Follicular lymphoma (FL) treatment initiation is largely determined by tumor burden and symptoms. In the pre-rituximab era, the Group d’Etude des Lymphomes Folliculaires (GELF) developed widely adopted criteria to identify high tumor burden FL patients to harmonize clinical trial populations. The utilization of GELF criteria (GELFc) in routine therapeutic decision-making is poorly described. This multicenter retrospective study evaluated patterns of GELFc at presentation and GELFc utilization in therapeutic decision-making in newly diagnosed, advanced-stage rituximab-era FL. Associations between GELFc, treatment given, and patient survival were analyzed in 300 eligible cases identified between 2002-2019. One hundred and sixty-three (54%) had ≥1 GELFc at diagnosis. The presence or cumulative number of GELFc did not predict progression-free survival in patients undergoing watch-and-wait (W&W) or those receiving systemic treatment. Of interest, in patients with ≥1 GELFc, 16 of 163 (10%) underwent initial W&W (comprising 22% of the W&W cohort). In those receiving systemic therapy +/- radiotherapy, 74 of 215 (34%) met no GELFc. Our data suggest clinicians are using adjunctive measures to make decisions regarding treatment initiation in a significant proportion of patients. By restricting FL clinical trial eligibility only to those meeting GELFc, reported outcomes may not be applicable to a significant proportion of patients treated in routine care settings.

Original language	English
Pages (from-to)	3338-3345
Number of pages	8
Journal	Haematologica
Volume	109
Issue number	10
DOIs	https://doi.org/10.3324/haematol.2023.284538
Publication status	Published - Oct 2024

Access to Document

10.3324/haematol.2023.284538

Cite this

Barraclough, A., Agrawal, S., Talaulikar, D., Chong, G., Yoo, E., Cheah, C. Y., Franco, N., Nguyen, B., Mutsando, H., Tahir, F., Trotman, J., Huang, J., Keane, C., Lincoln, M., Cochrane, T., Johnston, A. M., Dickinson, M., Opat, S., McQuilten, Z. K., ... Hawkes, E. A. (2024). Impact and utility of follicular lymphoma GELF criteria in routine care: an Australasian Lymphoma Alliance study. Haematologica, 109(10), 3338-3345. https://doi.org/10.3324/haematol.2023.284538

@article{feb8c2c2310d4eabb282f9b0c40e24e0,

title = "Impact and utility of follicular lymphoma GELF criteria in routine care: an Australasian Lymphoma Alliance study",

abstract = "Follicular lymphoma (FL) treatment initiation is largely determined by tumor burden and symptoms. In the pre-rituximab era, the Group d{\textquoteright}Etude des Lymphomes Folliculaires (GELF) developed widely adopted criteria to identify high tumor burden FL patients to harmonize clinical trial populations. The utilization of GELF criteria (GELFc) in routine therapeutic decision-making is poorly described. This multicenter retrospective study evaluated patterns of GELFc at presentation and GELFc utilization in therapeutic decision-making in newly diagnosed, advanced-stage rituximab-era FL. Associations between GELFc, treatment given, and patient survival were analyzed in 300 eligible cases identified between 2002-2019. One hundred and sixty-three (54%) had ≥1 GELFc at diagnosis. The presence or cumulative number of GELFc did not predict progression-free survival in patients undergoing watch-and-wait (W&W) or those receiving systemic treatment. Of interest, in patients with ≥1 GELFc, 16 of 163 (10%) underwent initial W&W (comprising 22% of the W&W cohort). In those receiving systemic therapy +/- radiotherapy, 74 of 215 (34%) met no GELFc. Our data suggest clinicians are using adjunctive measures to make decisions regarding treatment initiation in a significant proportion of patients. By restricting FL clinical trial eligibility only to those meeting GELFc, reported outcomes may not be applicable to a significant proportion of patients treated in routine care settings.",

author = "Allison Barraclough and Shivam Agrawal and Dipti Talaulikar and Geoffrey Chong and Edward Yoo and Cheah, {Chan Y.} and Nunzio Franco and Bianca Nguyen and Howard Mutsando and Fatima Tahir and Judith Trotman and Jing Huang and Colm Keane and Mitchel Lincoln and Tara Cochrane and Johnston, {Anna M.} and Michael Dickinson and Stephen Opat and McQuilten, {Zoe K.} and Wood, {Erica M.} and George, {Gayathri St} and Hawkes, {Eliza A.}",

note = "Publisher Copyright: {\textcopyright}2024 Ferrata Storti Foundation.",

year = "2024",

month = oct,

doi = "10.3324/haematol.2023.284538",

language = "English",

volume = "109",

pages = "3338--3345",

journal = "Haematologica",

issn = "0390-6078",

publisher = "Ferrata Storti Foundation",

number = "10",

}

Barraclough, A, Agrawal, S, Talaulikar, D, Chong, G, Yoo, E, Cheah, CY, Franco, N, Nguyen, B, Mutsando, H, Tahir, F, Trotman, J, Huang, J, Keane, C, Lincoln, M, Cochrane, T, Johnston, AM, Dickinson, M, Opat, S, McQuilten, ZK, Wood, EM, George, GS & Hawkes, EA 2024, 'Impact and utility of follicular lymphoma GELF criteria in routine care: an Australasian Lymphoma Alliance study', Haematologica, vol. 109, no. 10, pp. 3338-3345. https://doi.org/10.3324/haematol.2023.284538

TY - JOUR

T1 - Impact and utility of follicular lymphoma GELF criteria in routine care

T2 - an Australasian Lymphoma Alliance study

AU - Barraclough, Allison

AU - Agrawal, Shivam

AU - Talaulikar, Dipti

AU - Chong, Geoffrey

AU - Yoo, Edward

AU - Cheah, Chan Y.

AU - Franco, Nunzio

AU - Nguyen, Bianca

AU - Mutsando, Howard

AU - Tahir, Fatima

AU - Trotman, Judith

AU - Huang, Jing

AU - Keane, Colm

AU - Lincoln, Mitchel

AU - Cochrane, Tara

AU - Johnston, Anna M.

AU - Dickinson, Michael

AU - Opat, Stephen

AU - McQuilten, Zoe K.

AU - Wood, Erica M.

AU - George, Gayathri St

AU - Hawkes, Eliza A.

PY - 2024/10

Y1 - 2024/10

N2 - Follicular lymphoma (FL) treatment initiation is largely determined by tumor burden and symptoms. In the pre-rituximab era, the Group d’Etude des Lymphomes Folliculaires (GELF) developed widely adopted criteria to identify high tumor burden FL patients to harmonize clinical trial populations. The utilization of GELF criteria (GELFc) in routine therapeutic decision-making is poorly described. This multicenter retrospective study evaluated patterns of GELFc at presentation and GELFc utilization in therapeutic decision-making in newly diagnosed, advanced-stage rituximab-era FL. Associations between GELFc, treatment given, and patient survival were analyzed in 300 eligible cases identified between 2002-2019. One hundred and sixty-three (54%) had ≥1 GELFc at diagnosis. The presence or cumulative number of GELFc did not predict progression-free survival in patients undergoing watch-and-wait (W&W) or those receiving systemic treatment. Of interest, in patients with ≥1 GELFc, 16 of 163 (10%) underwent initial W&W (comprising 22% of the W&W cohort). In those receiving systemic therapy +/- radiotherapy, 74 of 215 (34%) met no GELFc. Our data suggest clinicians are using adjunctive measures to make decisions regarding treatment initiation in a significant proportion of patients. By restricting FL clinical trial eligibility only to those meeting GELFc, reported outcomes may not be applicable to a significant proportion of patients treated in routine care settings.

AB - Follicular lymphoma (FL) treatment initiation is largely determined by tumor burden and symptoms. In the pre-rituximab era, the Group d’Etude des Lymphomes Folliculaires (GELF) developed widely adopted criteria to identify high tumor burden FL patients to harmonize clinical trial populations. The utilization of GELF criteria (GELFc) in routine therapeutic decision-making is poorly described. This multicenter retrospective study evaluated patterns of GELFc at presentation and GELFc utilization in therapeutic decision-making in newly diagnosed, advanced-stage rituximab-era FL. Associations between GELFc, treatment given, and patient survival were analyzed in 300 eligible cases identified between 2002-2019. One hundred and sixty-three (54%) had ≥1 GELFc at diagnosis. The presence or cumulative number of GELFc did not predict progression-free survival in patients undergoing watch-and-wait (W&W) or those receiving systemic treatment. Of interest, in patients with ≥1 GELFc, 16 of 163 (10%) underwent initial W&W (comprising 22% of the W&W cohort). In those receiving systemic therapy +/- radiotherapy, 74 of 215 (34%) met no GELFc. Our data suggest clinicians are using adjunctive measures to make decisions regarding treatment initiation in a significant proportion of patients. By restricting FL clinical trial eligibility only to those meeting GELFc, reported outcomes may not be applicable to a significant proportion of patients treated in routine care settings.

UR - http://www.scopus.com/inward/record.url?scp=85205514400&partnerID=8YFLogxK

U2 - 10.3324/haematol.2023.284538

DO - 10.3324/haematol.2023.284538

M3 - Article

C2 - 38450504

AN - SCOPUS:85205514400

SN - 0390-6078

VL - 109

SP - 3338

EP - 3345

JO - Haematologica

JF - Haematologica

IS - 10

ER -

Impact and utility of follicular lymphoma GELF criteria in routine care: an Australasian Lymphoma Alliance study

Abstract

Access to Document

Other files and links

Fingerprint

Cite this